AbbVie, a global pharmaceutical company headquartered in North Chicago, is acquiring Madison-based Nimble Therapeutics for ...

Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across ...

AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN) have a lot in common. Both also recently saw their shares fall significantly in ...

AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics. The impending acquisition will add Nimble’s lead preclinical asset ...

"Nimble Therapeutics is committed to transforming the discovery of oral peptide-based medicines. With AbbVie's world-class expertise in developing and commercializing medicines on a global scale ...

AbbVie will acquire Nimble Therapeutics, according to a newly announced agreement. As a result, Nimble’s peptide synthesis, screening, and optimization platform will be added the AbbVie’s portfolio, ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...

"Nimble Therapeutics is committed to transforming the discovery of oral peptide-based medicines. With AbbVie's world-class expertise in developing and commercializing medicines on a global scale, ...